Last updated: February 24, 2026
What is the drug identified by NDC 76204-0100?
NDC 76204-0100 refers to Tafasitamab-cxix, marketed as Monjuvi, a CD19-targeting monoclonal antibody approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The drug is used in combination with lenalidomide after at least two prior systemic therapies.
Market Overview
The global hematologic malignancy treatment market, particularly the targeted therapies segment, is expanding rapidly. The key factors influencing this segment include:
- Rising incidence of DLBCL.
- Advancements in monoclonal antibody therapies.
- Increasing approvals for combination regimens.
- Growing adoption in developed markets.
Market Size and Growth
Estimated global market size for DLBCL therapies was valued at approximately USD 2.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8.5% through 2030, driven by:
- Increased diagnosis rates.
- Broader approval of targeted agents.
- Expanded indications.
Competitive Landscape
Major competitors include:
- Rituximab (Rituxan)
- Polatuzumab vedotin (Polivy)
- Tafasitamab (Monjuvi)
- CAR-T therapies (e.g., AstraZeneca’s Breyanzi, Gilead's Yescarta)
Tafasitamab-cxix positions as a targeted option post-anti-CD20 therapy failure, filling a niche with a differentiated profile.
Clinical Positioning
Monjuvi’s approval in combination with lenalidomide has positioned it favorably for third-line treatment, especially in patients ineligible for stem cell transplant.
Price Analysis
Current Pricing
- The average wholesale price (AWP) in the U.S. for Monjuvi is approximately USD 9,000 per 50 mg vial.
- The typical treatment course involves multiple vials, with a standard dosage of 12 mg/kg administered weekly for the first 3 cycles and then every 2 weeks.
| Dosage |
Estimated Cost per Treatment Cycle |
| 600 mg (average patient weight 75 kg) |
USD 108,000 |
The estimated total cost for a standard 6-cycle course exceeds USD 600,000 per patient.
Price Trends
- The initial approval in 2020 led to a pricing baseline of USD 7,500 per vial.
- Prices increased by approximately 20% over 2 years due to manufacturing costs and market positioning policies.
- Payer negotiations, segment competition, and potential biosimilar entry could impact future pricing.
Market Access and Reimbursement
U.S. payers generally reimburse at levels close to AWP, with hospitals applying a 10-20% markup. Access depends on formulary inclusion, with specialty pharmacies playing a critical role.
International markets vary:
- European Union: Price points range from EUR 6,500 to EUR 9,000 per vial.
- Canada: Prices range from CAD 11,000 to CAD 13,000 per vial.
Lower-income countries face pricing challenges, often limited to compassionate use or generic options.
Price Projection (2023–2030)
| Year |
Expected Price Range per Vial (USD) |
Key Factors Impacting Price |
| 2023 |
USD 9,000 – USD 9,500 |
Market stabilization, inflation adjustments |
| 2025 |
USD 8,500 – USD 9,300 |
Increased competition, biosimilar development |
| 2027 |
USD 8,000 – USD 9,000 |
Biosimilar market entry, policy reforms |
| 2030 |
USD 7,500 – USD 8,500 |
Biosimilar proliferation, negotiated discounts |
Fragmentation in the monoclonal antibody market and biosimilar approval timelines suggest downward pressure on prices over the next decade.
Regulatory and Policy Impacts
The FDA’s push toward biosimilars and cost-containment strategies could pressure Monjuvi prices. Reimbursement policies emphasizing value-based agreements may further modulate pricing strategies, especially in the U.S. and EU.
Key Takeaways
- NDC 76204-0100 (Tafasitamab-cxix) occupies a niche in the treatment of relapsed/refractory DLBCL, with a current U.S. wholesale price of approximately USD 9,000 per vial.
- The total treatment cost exceeds USD 600,000 per patient, highlighting significant market size and revenue potential.
- Price trends suggest modest declines over the next decade driven by biosimilar competition and policy reforms.
- International pricing varies, with lower prices in emerging markets and higher prices in developed nations.
- Market growth hinges on regulatory approvals, clinical adoption, and payer negotiations.
FAQs
1. How does Monjuvi compare to its competitors?
Monjuvi offers a targeted CD19 therapy for relapsed/refractory DLBCL, filling a treatment gap post-anti-CD20 therapy. Its combination with lenalidomide provides a differentiated mechanism relative to CAR-T therapies and other monoclonals.
2. What are the main cost drivers for Monjuvi?
Manufacturing expenses, R&D investments, and market positioning influence pricing. The complex biologic production and rarity of the indication contribute to high costs.
3. Will biosimilars enter the market soon?
Biosimilar approval processes are progressing globally. In the U.S., upcoming biosimilar submissions could arrive as early as 2024-2025, with market entry expected within 2-3 years afterward.
4. How are payers influencing pricing strategies?
Payers are increasingly negotiating value-based agreements and demanding lower prices, particularly in mature markets, to contain costs.
5. What is the outlook for international markets?
Price levels vary with healthcare system structures, but growth is anticipated in regions with expanding oncology treatments and increasing diagnosis rates, such as Asia-Pacific.
References
[1] Market Research Future. (2022). Hematologic Malignancies Market Report.
[2] IQVIA. (2022). Global Oncology Market Data.
[3] U.S. Food and Drug Administration. (2020). Approval details for Monjuvi.
[4] European Medicines Agency. (2021). Biosimilar approval timelines.
[5] CMS. (2022). Reimbursement policies for biologics in the U.S.
